Licenses, Asset Acquisitions and Contingent Consideration - Additional Information (Details) - USD ($)				1 Months Ended		3 Months Ended
	May 11, 2020	Jun. 24, 2018	Oct. 02, 2017	Jun. 30, 2018	Oct. 31, 2017	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
In process research and development				$ 20,000,000		$ 20,000	$ 30,000
Pulmokine, Inc. | License Agreement | In Process Research And Development Seralutinib
Business Acquisition [Line Items]
Product license term (in years)			10 years
Upfront payment					$ 5,500,000
Milestones accrued						0		$ 5,000,000
Pulmokine, Inc. | License Agreement | In Process Research And Development Seralutinib | Maximum
Business Acquisition [Line Items]
Development and regulatory milestone payments, payable			$ 58,000,000
Commercial milestone payments, payable			45,000,000
Sales milestone payments, payable			$ 190,000,000
Aerpio Pharmaceuticals, Inc. | License Agreement | In Process Research And Development G B Zero Zero Four
Business Acquisition [Line Items]
Upfront payment	$ 15,000,000
Milestones accrued						$ 0
Participation rights (as a percent)		20.00%
Aerpio Pharmaceuticals, Inc. | License Agreement | In Process Research And Development G B Zero Zero Four | Maximum
Business Acquisition [Line Items]
Development and regulatory milestone payments, payable	40,000,000
Sales milestone payments, payable	$ 50,000,000